None
SEDAR Interim Financial Statements
MDMA · Price
[
{
"companyName": "PharmAla Biotech Holdings Inc.",
"reportingPeriodEnd": "2025-11-30",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cash": 83523,
"shortTermInvestments": 773529,
"accountsReceivable": 153582,
"hstReceivable": 20644,
"prepaidExpensesDepositsAndOtherAssets": 256072,
"inventory": 357666,
"totalCurrentAssets": 1645016,
"equipment": 2603,
"intangibleAssets": 1751552,
"totalAssets": 3399171,
"accountsPayablesAndAccruedLiabilities": 467439,
"customerDepositsAndDeferredRevenue": 433232,
"deferredJointVentureDownstreamSales": 126787,
"totalCurrentLiabilities": 1027458,
"totalLiabilities": 1027458,
"shareCapital": 7743458,
"contributedSurplus": 941234,
"warrants": 1227906,
"deficit": -7540884,
"totalShareholdersEquity": 2371714,
"derivedMetrics": {
"cashPerShare": 0.0008,
"workingCapitalPerShare": 0.0057
}
},
"incomeStatement": {
"revenue": 206440,
"costOfGoodsSold": 34837,
"grossProfit": 171603,
"expenses": {
"consulting": 30749,
"depreciationAndAmortization": 29757,
"investorRelations": 16841,
"officeAndGeneral": 52286,
"researchCosts": 41098,
"payrollExpenses": 102009,
"professionalFees": 119414,
"stockBasedCompensation": 106592,
"lossOnDebtSettlement": 66047,
"travel": 16505,
"totalExpenses": 581298
},
"netLossAndComprehensiveLoss": -409695,
"netLossPerShare": -0.01,
"weightedAverageSharesOutstanding": 108009123
},
"cashFlowStatement": {
"operatingActivities": {
"lossForThePeriod": -409695,
"adjustmentsForNonCashItems": {
"depreciationAndAmortization": 29757,
"stockBasedCompensation": 106592,
"lossOnDebtSettlement": 66047,
"accruedInterestIncome": -23529
},
"changesInWorkingCapital": {
"accountsReceivable": -115791,
"hstReceivable": 104,
"prepaidExpensesDepositsAndOtherAssets": 1884,
"inventory": 12043,
"accountsPayablesAndAccruedLiabilities": 59170,
"customerDepositsAndDeferredRevenue": 157197
},
"netCashUsedInOperatingActivities": -116221
},
"investingActivities": {
"intangibleAssets": -10916,
"redemptionOfInvestments": 170473,
"netCashProvidedByInvestingActivities": 159557
},
"financingActivities": {
"proceedsFromExerciseOfStockOptions": 0,
"netCashProvidedByFinancingActivities": 0
},
"netIncreaseInCash": 43336,
"cashBeginningOfPeriod": 40187,
"cashEndOfPeriod": 83523
},
"investmentsAndOtherAssets": [
{
"type": "Marketable Securities",
"description": "GIC with principal $750,000, rate 3.45%, maturity Jan 2, 2026",
"ownershipPercentage": null,
"value": 773529,
"notes": "Denominated in CAD, cashable at any time, measured at amortized cost."
},
{
"type": "Joint Venture",
"description": "Cortexa Pty Ltd, 50% equity interest, exclusive rights to manufacture and distribute MDMA and Psilocybin in Australia",
"ownershipPercentage": 50,
"value": null,
"notes": "Accounted for using equity method, share of losses recognized."
}
],
"shareStructure": {
"authorizedShares": "unlimited",
"issuedShares": 108618465,
"classesOfShares": ["common shares"],
"warrants": [
{
"number": 1973331,
"exercisePrice": 0.27,
"expiryDate": "2027-04-19"
},
{
"number": 4338111,
"exercisePrice": 0.27,
"expiryDate": "2027-12-20"
}
],
"options": [
{
"number": 160000,
"exercisePrice": 0.05,
"expiryDate": "2026-03-23"
},
{
"number": 525000,
"exercisePrice": 0.1,
"expiryDate": "2026-06-18"
},
{
"number": 80000,
"exercisePrice": 0.1,
"expiryDate": "2026-08-12"
},
{
"number": 750000,
"exercisePrice": 0.1,
"expiryDate": "2027-01-05"
},
{
"number": 1500000,
"exercisePrice": 0.1,
"expiryDate": "2027-01-05"
},
{
"number": 300000,
"exercisePrice": 0.1,
"expiryDate": "2027-07-13"
},
{
"number": 2300000,
"exercisePrice": 0.18,
"expiryDate": "2033-11-06"
},
{
"number": 1400000,
"exercisePrice": 0.105,
"expiryDate": "2030-05-29"
},
{
"number": 1000000,
"exercisePrice": 0.12,
"expiryDate": "2030-10-03"
}
],
"rightsConvertibleInstruments": null
},
"managementCompensation": {
"currency": "CAD",
"periods": {
"2025-11-30": {
"salaries": 117159,
"shareBased": 41779,
"total": 158938
},
"2024-11-30": {
"salaries": 87000,
"shareBased": 118906,
"total": 205906
}
},
"namedIndividuals": [
{
"name": "CEO",
"title": "Chief Executive Officer",
"period": "2025-11-30",
"components": {
"salary": 42500,
"bonus": 0,
"total": 55156
}
},
{
"name": "COO",
"title": "Chief Operating Officer",
"period": "2025-11-30",
"components": {
"salary": 23500,
"bonus": 0,
"total": 31979
}
},
{
"name": "CFO",
"title": "Chief Financial Officer",
"period": "2025-11-30",
"components": {
"salary": 22500,
"bonus": 0,
"total": 40613
}
},
{
"name": "CCO",
"title": "Chief Commercial Officer",
"period": "2025-11-30",
"components": {
"salary": 28659,
"bonus": 0,
"total": 31190
}
}
],
"otherRelatedPartyTransactions": [
{
"counterparty": "Company owned by CFO",
"description": "Consulting fees",
"amount": 22500,
"period": "2025-11-30"
},
{
"counterparty": "Companies owned by CCO",
"description": "Services as CCO and legal services",
"amount": 28659,
"period": "2025-11-30"
}
]
},
"subsequentEvents": [
{
"eventDate": null,
"description": "250,000 RSUs vested and issued to the CFO",
"impactValue": null
},
{
"eventDate": null,
"description": "18,750 RSUs vested to the director of PharmAla Australia",
"impactValue": null
}
]
}
]
More from Pharmala Biotech Holdings Inc
May 20, 2026 · 08:15